Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien Purchases 100,000 Shares

Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien bought 100,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was purchased at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $56.17 on Friday. The stock has a market cap of $8.52 billion, a P/E ratio of 27.00, a P/E/G ratio of 2.31 and a beta of 1.20. The firm’s 50-day simple moving average is $61.63 and its 200 day simple moving average is $64.77. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. During the same quarter last year, the firm posted $0.74 earnings per share. The firm’s quarterly revenue was up 16.4% compared to the same quarter last year. Equities analysts expect that Bruker Co. will post 2.4 EPS for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.36%. Bruker’s dividend payout ratio (DPR) is 9.62%.

Analysts Set New Price Targets

A number of brokerages have weighed in on BRKR. Barclays dropped their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company dropped their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Citigroup decreased their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen cut their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Finally, Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $79.36.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FMR LLC grew its position in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares during the last quarter. State Street Corp raised its position in shares of Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after purchasing an additional 318,808 shares during the period. RTW Investments LP lifted its holdings in shares of Bruker by 1.1% during the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after purchasing an additional 37,024 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the period. Finally, Marshall Wace LLP increased its stake in Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.